Jeremy Chadwick Sells 12,905 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 12,905 shares of Kymera Therapeutics stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $79.36, for a total transaction of $1,024,140.80. Following the transaction, the chief operating officer owned 48,297 shares in the company, valued at approximately $3,832,849.92. This trade represents a 21.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Stock Performance

KYMR opened at $81.46 on Friday. Kymera Therapeutics, Inc. has a fifty-two week low of $28.50 and a fifty-two week high of $103.00. The firm’s fifty day moving average is $83.29 and its 200 day moving average is $79.30. The stock has a market cap of $6.70 billion, a price-to-earnings ratio of -22.82 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. During the same quarter in the previous year, the company earned ($0.82) EPS. Kymera Therapeutics’s revenue for the quarter was up 55.5% on a year-over-year basis. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current year.

Hedge Funds Weigh In On Kymera Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in KYMR. Smartleaf Asset Management LLC grew its stake in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after buying an additional 349 shares in the last quarter. Osaic Holdings Inc. grew its stake in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares in the last quarter. Bessemer Group Inc. grew its stake in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after buying an additional 815 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Kymera Therapeutics in the 4th quarter worth $63,000.

Wall Street Analyst Weigh In

KYMR has been the subject of several research analyst reports. Jefferies Financial Group initiated coverage on shares of Kymera Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $110.00 target price for the company. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $108.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Piper Sandler raised their target price on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. BTIG Research cut their target price on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $119.00 target price on shares of Kymera Therapeutics in a research note on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $118.10.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.